Literature DB >> 18693168

Molecular aspects of carcinogenesis in pancreatic cancer.

Alexandros Koliopanos1, Constantinos Avgerinos, Constantina Paraskeva, Zisis Touloumis, Dionisisa Kelgiorgi, Christos Dervenis.   

Abstract

BACKGROUND: Pancreatic cancer (PCa) is one of the most aggressive human solid tumors, with rapid growth and metastatic spread as well as resistance to chemotherapeutic drugs, leading rapidly to virtually incurable disease. Over the last 20 years, however, significant advances have been made in our understanding of the molecular biology of PCa, with a focus on the cytogenetic abnormalities in PCa cell growth and differentiation. DATA SOURCES: A MEDLINE search and manual cross-referencing were utilized to identify published data for PCa molecular biology studies between 1986 and 2008, with emphasis on genetic alterations and developmental oncology.
RESULTS: Activation of oncogenes, deregulation of tumor suppressor and genome maintenance genes, upregulation of growth factors/growth factor receptor signaling cascade systems, and alterations in cytokine expression, have been reported to play important roles in the process of pancreatic carcinogenesis. Alterations in the K-ras proto-oncogene and the p16INK4a, p53, FHIT, and DPC4 tumor suppressor genes occur in a high percentage of tumors. Furthermore, a variety of growth factors are expressed at increased levels. In addition, PCa often exhibits alterations in growth inhibitory pathways and evades apoptosis through p53 mutations and aberrant expression of apoptosis-regulating genes, such as members of the Bcl family. Additional pathways in the development of an aggressive phenotype, local infiltration and metastasis are still under ongoing genetic research. The present paper reviews recent studies on the pathogenesis of PCa, and includes a brief reference to alterations reported for other types of pancreatic tumor.
CONCLUSIONS: Advances in molecular genetics and biology have improved our perception of the pathogenesis of PCa. However, further studies are needed to better understand the fundamental changes that occur in PCa, thus leading to better diagnostic and therapeutic management.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18693168

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  16 in total

1.  The Id3/E47 axis mediates cell-cycle control in human pancreatic ducts and adenocarcinoma.

Authors:  Seung-Hee Lee; Ergeng Hao; Alice Kiselyuk; James Shapiro; David J Shields; Andrew Lowy; Fred Levine; Pamela Itkin-Ansari
Journal:  Mol Cancer Res       Date:  2011-04-15       Impact factor: 5.852

2.  Beta-adrenergic signaling in the development and progression of pulmonary and pancreatic adenocarcinoma.

Authors:  Hildegard M Schuller; Hussein A N Al-Wadei
Journal:  Curr Cancer Ther Rev       Date:  2012-05-01

Review 3.  Pancreatic cancer: pathobiology, treatment options, and drug delivery.

Authors:  Jing Li; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-03-03       Impact factor: 4.009

4.  Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.

Authors:  Hedy Lee Kindler; Kristen Wroblewski; James A Wallace; Michael J Hall; Gershon Locker; Sreenivasa Nattam; Edem Agamah; Walter M Stadler; Everett E Vokes
Journal:  Invest New Drugs       Date:  2010-08-28       Impact factor: 3.850

5.  Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor alpha by inhibiting NF-kappaB signaling pathway.

Authors:  Chenghai Li; Zhengfeng Yang; Chunyan Zhai; Wenwei Qiu; Dali Li; Zhengfang Yi; Lei Wang; Jie Tang; Min Qian; Jian Luo; Mingyao Liu
Journal:  Mol Cancer       Date:  2010-04-06       Impact factor: 27.401

6.  Aberrant crypt focus and fragile histidine triad protein in sporadic colorectal carcinoma.

Authors:  Kim Vaiphei; Aruna Rangan; Rajinder Singh
Journal:  World J Gastrointest Oncol       Date:  2012-12-15

7.  Nicotinic receptor-associated modulation of stimulatory and inhibitory neurotransmitters in NNK-induced adenocarcinoma of the lungs and pancreas.

Authors:  Hussein A N Al-Wadei; Hildegard M Schuller
Journal:  J Pathol       Date:  2009-08       Impact factor: 7.996

8.  Characterization of a novel curcumin analog P1 as potent inhibitor of the NF-κB signaling pathway with distinct mechanisms.

Authors:  Yan-min Peng; Jian-bin Zheng; Yu-bo Zhou; Jia Li
Journal:  Acta Pharmacol Sin       Date:  2013-04-22       Impact factor: 6.150

Review 9.  Fragile histidine triad protein: structure, function, and its association with tumorogenesis.

Authors:  Md Imtaiyaz Hassan; Abdullah Naiyer; Faizan Ahmad
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-24       Impact factor: 4.553

Review 10.  Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.

Authors:  Paul Dent; David T Curiel; Paul B Fisher; Steven Grant
Journal:  Drug Resist Updat       Date:  2009-04-22       Impact factor: 18.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.